|
gptkbp:instance_of
|
gptkb:item
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Gn_RH_agonists
gptkb:Lupron
gptkb:Trelstar
|
|
gptkbp:activities
|
Gn RH receptor agonist
|
|
gptkbp:approves
|
gptkb:1985
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Lupron
gptkb:Eligard
Viadur
|
|
gptkbp:class
|
hormonal agent
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
hypersensitivity to leuprolide
|
|
gptkbp:discovered_by
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
injectable solution
implant
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
leuprolide
|
|
gptkbp:ingredients
|
C59 H84 N16 O13 S
|
|
gptkbp:interacts_with
|
anticoagulants
hormonal contraceptives
antidiabetic medications
|
|
gptkbp:is_atype_of
|
L02 A E01
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
gptkb:endometriosis
precocious puberty
uterine fibroids
|
|
gptkbp:lifespan
|
3 hours
|
|
gptkbp:manager
|
intramuscular injection
subcutaneous injection
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:scholarships
|
report any unusual bleeding
regular follow-up appointments required
discuss fertility preservation options
may affect bone density
monitor for signs of allergic reaction
|
|
gptkbp:side_effect
|
fatigue
weight gain
mood changes
hot flashes
decreased libido
|
|
gptkbp:social_structure
|
gptkb:protein
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:type_of
|
74381-53-6
|